Wang Hao, Gu Zhitao, Ding Jianyong, Tan Lijie, Fu Jianhua, Shen Yi, Wei Yucheng, Zhang Peng, Han Yongtao, Chen Chun, Zhang Renquan, Li Yin, Chen Keneng, Chen Hezhong, Liu Yongyu, Cui Youbing, Wang Yun, Pang Liewen, Yu Zhentao, Zhou Xinming, Liu Yangchun, Liu Yuan, Fang Wentao
1 Department of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, China ; 2 Department of Thoracic Surgery, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai 200030, China ; 3 Department of Thoracic Surgery, Guangdong Esophageal Cancer Institute, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou 510060, China ; 4 Department of Thoracic Surgery, Affiliated Hospital of Qingdao University, Qingdao 266001, China ; 5 Department of Endocrinology, Tianjin Medical University General Hospital, Tianjin 300052, China ; 6 Department of Thoracic Surgery, Sichuan Cancer Hospital, Chengdu 610041, China ; 7 Department of Thoracic Surgery, Fujian Medical University Union Hospital, Fuzhou 350001, China ; 8 Department of Thoracic Surgery, First Affiliated Hospital of Anhui Medical University, Hefei 230022, China ; 9 Department of Thoracic Surgery, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou 450008, China ; 10 Department of Thoracic Surgery, Beijing Cancer Hospital, Beijing 100142, China ; 11 Department of Cardiothoracic Surgery, Changhai Hospital, Shanghai 200433, China ; 12 Department of Thoracic Surgery, Liaoning Cancer Hospital, Shenyang 110042, China ; 13 Department of Thoracic Surgery, First Affiliated Hospital of Jilin University, Changchun 130021, China ; 14 Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu 610041, China ; 15 Department of Thoracic Surgery, Huashan Hospital, Fudan University, Shanghai 200032, China ; 16 Department of Esophageal Cancer, Tianjin Cancer Hospital, Tianjin 300060, China ; 17 Department of Thoracic Surgery, Zhejiang Cancer Hospital, Hangzhou 310022, China ; 18 Department of Thoracic Surgery, Jiangxi People's Hospital, Nanchang 330006, China.
J Thorac Dis. 2016 Apr;8(4):673-9. doi: 10.21037/jtd.2016.03.05.
Video-assisted thoracoscopic surgery (VATS) theoretically offers advantages over open thymectomy for clinically early-stage (Masaoka-Koga stage I and II) thymic malignancies. However, long-term outcomes have not been well studied. We compared the postoperative outcomes and survival from a cohort study based on the database of the Chinese Alliance for Research in Thymomas (ChART).
Between 1994 and 2012, data of 1,117 patients having surgery for clinically early-stage (Masaoka-Koga stage I and II) tumors were enrolled for the study. Among them, 241 cases underwent VATS thymectomy (VATS group), while 876 cases underwent open thymectomy (Open group). Univariate analyses were used to compare the clinical character and perioperative outcomes between the two groups. And multivariate analysis was performed to determine the independent predictive factors for long-term survival.
Compared with the Open group, the VATS group had higher percentage of total thymectomy (80.5% vs. 73.9%, P=0.028), resection rate (98.8% vs. 88.7%, P=0.000) and less recurrence (2.9% vs. 16.0%, P=0.000). Five-year overall survival was 92% after VATS and 92% after open thymectomy, with no significant difference between the two groups (P=0.15). However, 5-year disease free survival were 92% in VATS group and 83% in Open group (P=0.011). Cox proportional hazards model revealed that WHO classification, Masaoka-Koga stage and adjuvant therapy were independent predictive factors for overall survival, while surgical approach had no significant impact on long-term outcome.
This study suggests that VATS thymectomy is an effective approach for clinically early-stage thymic malignancies. And it may offer better perioperative outcomes, as well as equal oncological survival.
对于临床早期(马萨oka - 古贺分期I和II期)胸腺恶性肿瘤,电视辅助胸腔镜手术(VATS)理论上比开放性胸腺切除术具有优势。然而,长期结果尚未得到充分研究。我们基于中国胸腺瘤研究联盟(ChART)的数据库进行队列研究,比较了术后结果和生存率。
1994年至2012年期间,纳入1117例因临床早期(马萨oka - 古贺分期I和II期)肿瘤接受手术的患者数据进行研究。其中,241例接受VATS胸腺切除术(VATS组),876例接受开放性胸腺切除术(开放组)。采用单因素分析比较两组的临床特征和围手术期结果。并进行多因素分析以确定长期生存的独立预测因素。
与开放组相比,VATS组全胸腺切除术的比例更高(80.5%对73.9%,P = 0.028),切除率更高(98.8%对88.7%,P = 0.000),复发率更低(2.9%对16.0%,P = 0.000)。VATS术后5年总生存率为92%,开放性胸腺切除术后为92%,两组之间无显著差异(P = 0.15)。然而,VATS组5年无病生存率为92%,开放组为83%(P = 0.011)。Cox比例风险模型显示,世界卫生组织分类、马萨oka - 古贺分期和辅助治疗是总生存的独立预测因素,而手术方式对长期结果无显著影响。
本研究表明,VATS胸腺切除术是治疗临床早期胸腺恶性肿瘤的有效方法。它可能提供更好的围手术期结果以及相同的肿瘤学生存率。